Cellular Therapy
From the Journals
Autologous stem-cell transplantation for scleroderma beats cyclophosphamide in long term
Hematopoietic toxicity should be weighed against the benefits of transplantation.
Conference Coverage
How to manage cytokine release syndrome
ATLANTA – Don’t wait to give anticytokine therapy.
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
Conference Coverage
Gene therapy regimen for XSCID shows rapid results in newly diagnosed infants
ATLANTA – The regimen combines a modified lentiviral vector with reduced exposure busulfan conditioning.
From the Journals
Cyclophosphamide after transplant reduced GVHD in myeloma patients
Anticancer agents may be more active after transplantation than before, researchers suggested.
News
FDA addresses cell-based regenerative medicine in comprehensive new policy
Clarifying the existing regulations will “promote responsible and flexible regulation that leverages science to advance public health,” according...
News
FDA approves letermovir for CMV prophylaxis
The FDA approved the use of letermovir tablets and injections to prevent CMV infection and disease in adults exposed to the virus who have had an...
Conference Coverage
Anidulafungin effectively treated invasive pediatric candidiasis in open-label trial
SAN DIEGO – The intravenous echinocandin anidulafungin effectively treated invasive candidiasis in children, with a safety profile resembling that...
Conference Coverage
Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse events
CHICAGO – In a review of patients treated with nivolumab, 27 of 34 who were refractory to corticosteroids and treated with tocilizumab for high-...
From the Journals
Off-the-shelf T cells used to treat viral infections after HSCT
Study suggests an effective way to get around the limitations of adoptive VST transfer.
From the Journals
ALLOZITHRO trial: HSCT patients fared worse with azithromycin
Early azithromycin in patients undergoing allogeneic hematopoietic stem cell transplant resulted in worse airflow decline–free survival than did...